Azathioptrine in Refractory Tolosa-Hunt Syndrome: Two Case Report
Downloads
Introduction: Tolosa-Hunt syndrome (THS) is an inflammatory disease with painful ophthalmoplegia and unilateral periorbital headache as detailed by the International Classification of Headache Disorders, 3rd edition (ICHD-3). Azathioprine has been suggested as a second-line treatment in refractory THS when oral corticosteroid only gives a partial response. Case: Two cases of THS, 45-year-old and 41-year-old women with unilateral headache, drooping of the left upper eyelid, and diplopia. They presented with complete ophthalmoplegia and ophthalmic division of trigeminal nerve disturbance. Magnetic resonance imaging (MRI) showed thickening of the left cavernous sinus, suggesting THS, while the other was normal. Corticosteroid (prednisone 1-1,5 mg/day) was given orally for the first two weeks, and according to the Numeric Pain Rating Scale (NPRS), pain intensity was reduced from severe to moderate. As a second-line treatment, azathioprine (2 mg/kg/day) was given afterward, with a significant reduction in pain intensity and remission of ophthalmoplegia within seven days. Azathioprine was used as an immunosuppressive agent and was continued for another three months without any deterioration in neurological deficits. The levels of complement 3, 4 (C3, C4), and C-reactive protein (CRP) were normal in both patients, with a slight increase in erythrocyte sedimentation rate (ESR) and equivocal values on antinuclear antibody (ANA) results. Other differentials of THS were eliminated from history-taking, physical examination, and proper investigations. Conclusion: Azathioprine as a second-line treatment can be used instead of an oral corticosteroid for refractory cases of THS with fewer side effects. Complete remission of ophthalmoplegia and a significant reduction in pain intensity was obtained.
Olesen J. Headache classification committee of the International classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211
Chaudhary V, Venu S, Deswal J. Painful ophthalmoplegia due to Tolosa-Hunt syndrome: A case report. Int J Med Sci Public Heal. 2016;5:1045-8
Arshad A, Nabi S, Panhwar MS, Rahil A. Tolosa-Hunt syndrome: An arcane pathology of cavernous venous sinus. BMJ Case Rep. 2015;2015.
Msigwa S, Li Y, Cheng X. Tolosa Hunt syndrome: Current diagnostic challenges and treatment. Yangtze Med. 2020;4(2):140–56.
Murtaza G, Konowitz N, Lu H, Faqah A, Kuruvilla A. An interesting case of Tolosa-Hunt syndrome in a young male. J Investig Med High Impact Case Rep. 2017;5(1).
Samatra D, Kesanda M, Indrayani D. Chronic granulomatous Tolosa-Hunt syndrome (case report). Bali Med J. 2016;5(1):20-2.
Hao R, He Y, Zhang H, Zhang W, Li X, Ke T. The evaluation of ICHD-3 beta diagnostic criteria for Tolosa–Hunt syndrome: A study of 22 cases of Tolosa–Hunt syndrome. Neurol Sci. 2015;36:899–905.
Borooah M, Ekka J, Ghosh D. Tolosa-Hunt syndrome: A rare case report. IOSR J Dent Med Sci. 2018;17(3):40–3.
Zhang X, Zhang W, Liu R, Dong Z, Yu S. Factors that influence Tolosa-Hunt syndrome and the short-term response to steroid pulse treatment. J Neurol Sci. 2014;341(1–2):13–6.
Bugeme M, Cisse O, Mukuku O, Diop A. Tolosa–Hunt syndrome: A painful ophthalmoplegia. Case Rep Neurol Med. 2020;1–4.
Arora N, Rambhatla S. Azathioprine in orbital apex syndrome. Indian J Pharm Pharmacol. 2020;7(3):210–2.
Kwon HS, Kim TY, Kim JH, Bae JH, Koh SH, Choi H, et al. Use of methotrexate in the management of recurrent Tolosa-Hunt syndrome. Medicine (Baltimore). 2020;99(17):e19882.
Arthur A, Sivadasan A, Mannam P, Prabkhar AT, Aaron S, Mathew V, et al. Tolosa–Hunt syndrome: Long-Term outcome and role of steroid-sparing agents. Ann Indian Acad Neurol. 2020;23(2):201–5.
Kim H, Oh SY. The clinical features and outcomes of Tolosa-Hunt syndrome. BMC Ophthalmol. 2021;21(237):1–5.
Santos Junior M, Siva AE, Bonatti RC. Tolosa Hunt syndrome, a painful ophthalmoplegia. Rev Bras Oftalmol. 2019;78(4):271–3.
Copyright (c) 2022 Devi Ariani Sudibyo, Mohammad Saiful Ardhi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
